-
Mashup Score: 0Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma - 6 month(s) ago
Purpose At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe the pattern of tumor-acquired mutations, but their clinical relevance has yet to be established. Methods We performed whole-exome sequencing for 463 patients who presented with myeloma and were enrolled onto the National Cancer Research Institute Myeloma XI trial, for whom complete molecular cytogenetic and clinical outcome data were available. Results We identified 15 significantly mutated genes: IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, LTB, CYLD, and FGFR3. The mutational spectrum is dominated by mutations in the RAS (43%) and nuclear factor-κB (17%) pathways, but although they are prognostically neutral, they could be targeted therapeutically. Mutations in CCND1 and DNA repair pathway alterations (TP53, ATM, ATR, and
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma [Aug 17, 2015] Walker et al. @JCO_ASCO https://t.co/kjH9EunwM1 #mmsm #camoldx #PrecisionMedicine
-
-
Mashup Score: 0Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients - 9 month(s) ago
The t(11;14)(q13;q32) results in up-regulation of cyclin D1 and is the most common translocation detected in multiple myeloma, where it is also associated with
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients [2002] @Rfonsi1 et al. @BloodJournal https://t.co/6qf9WS1uKn #mmsm #camoldx
-
-
Mashup Score: 1Separating Innocuous “CHIP” Mutations From Ominous “CHOP” Mutations in Patients With Treated AML in Remission - 10 month(s) ago
Cappelli LV, Meggendorfer M, Baer C, . Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia. 2021; doi: 10.1038/s
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Separating Innocuous “CHIP” Mutations From Ominous “CHOP” Mutations in Patients With Treated AML in Remission [Oct 11, 2021] Fitzpatrick & Hasserjian @ASH_hematology The Hematologist https://t.co/WmobwY3wG2 #AML #leusm #mdssm #camoldx https://t.co/J0hDznscjy
-
-
Mashup Score: 0Webprogram Unavailable - 10 month(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis [Dec 14, 2021] Margarete A Fabre et al. LBA-2 #ASH21 https://t.co/UZJgM7JOVm #leusm #mdssm #camoldx
-
-
Mashup Score: 0Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis - Nature Genetics - 10 month(s) ago
Analysis of whole-exome sequencing data from 200,453 UK Biobank participants identifies loci associated with clonal hematopoiesis and highlights causal links between clonal hematopoiesis and other traits.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis [Jul 14, 2022] @siddhartha_kar et al. @NatureGenet https://t.co/oFYfcFwlME #camoldx https://t.co/hQfW82JW1h
-
-
Mashup Score: 0CHIP, ICUS, CCUS and other four-letter words - Leukemia - 10 month(s) ago
Clonal hematopoiesis can be identified by the presence of somatic mutations in blood or bone marrow even in individuals without a myeloid malignancy. Advances in DNA sequencing have led to the discovery that clonal hematopoiesis is remarkably common and occurs in a wide variety of settings, each often described by unique acronym. These distinctions can be useful as the implications of clonal…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
CHIP, ICUS, CCUS and other four-letter words [Jun 8, 2017] Bejar @LeukemiaJnl https://t.co/KIC78XHsHd #leusm #mdssm #camoldx https://t.co/3go8Cy0qav
-
-
Mashup Score: 0Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA - npj Precision Oncology - 10 month(s) ago
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that detects single-nucleotide variants, insertions/deletions, copy number…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Validation of a liquid biopsy assay (@TempusLabs xF) with molecular and clinical profiling of circulating tumor DNA [Jul 2, 2021] Finkle et al. npj Precision Oncology https://t.co/xFjMey93PM #PrecisionMedicine #LiquidBiopsy #camoldx #openaccess
-
-
Mashup Score: 1Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA - npj Precision Oncology - 11 month(s) ago
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that detects single-nucleotide variants, insertions/deletions, copy number…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Validation of a liquid biopsy assay (@TempusLabs xF) with molecular and clinical profiling of circulating tumor DNA [Jul 2, 2021] Finkle et al. npj Precision Oncology https://t.co/xFjMey93PM #PrecisionMedicine #LiquidBiopsy #camoldx #openaccess
-
-
Mashup Score: 0Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA - npj Precision Oncology - 11 month(s) ago
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that detects single-nucleotide variants, insertions/deletions, copy number…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Validation of a liquid biopsy assay (@TempusLabs xF) with molecular and clinical profiling of circulating tumor DNA [Jul 2, 2021] Finkle et al. npj Precision Oncology https://t.co/xFjMey93PM #PrecisionMedicine #LiquidBiopsy #camoldx #openaccess
-
-
Mashup Score: 0
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Molecular Genetic Testing Patterns in Newly Dx AML: CONNECT® Registry [May 18, 2017] @DanPollyea et al. Abstract: E923 #EHA22 https://t.co/NOvxkVe5nr #NCT01688011 #AMLsm #leusm #oncopath #camoldx #PrecisionMedicine https://t.co/WY1p7tOThu
-
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma [Aug 17, 2015] Walker et al. @JCO_ASCO https://t.co/kjH9EunwM1 #mmsm #camoldx #PrecisionMedicine Table 2. Actionable Mutations https://t.co/Y8WG1LcSNO